Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How do we manage patients with refractory or breakthrough emesis?

Matti S Aapro1, ,

  • 11 route du Muids, Clinique de Genolier, 1272 Genolier, Switzerland. aapro@cdg.ch

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|February 28, 2002
PubMed
Summary

Suboptimal treatment for acute and delayed emesis, including breakthrough and refractory cases, is common. Current interventions show limited evidence, necessitating further research for effective antiemetic guidelines.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Collaborative Funding Model to Improve Quality of Care for Metastatic Breast Cancer in Europe.

Current oncology (Toronto, Ont.)·2025
Same author

Geriatric Assessment: ASCO Global Guideline.

JCO global oncology·2025
Same author

6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7).

Breast (Edinburgh, Scotland)·2024
Same author

Comment on "Dexamethasone-sparing on days 2-4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)".

British journal of cancer·2024
Same author

Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment.

Expert review of pharmacoeconomics & outcomes research·2024
Same author

Capturing the holistic value of biosimilars in Europe - part 1: a historical perspective.

Expert review of pharmacoeconomics & outcomes research·2024

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Medicine

Background:

  • Acute and delayed emesis remain significant challenges in patient care.
  • Current antiemetic therapies, despite guidelines like the Perugia consensus, are often suboptimal.
  • Breakthrough and refractory emesis indicate potential inadequacies in existing treatment regimens.

Purpose of the Study:

  • To evaluate the effectiveness of current interventions for breakthrough and refractory emesis.
  • To identify potential therapeutic strategies for managing difficult-to-treat emesis.
  • To highlight the need for evidence-based guidelines in antiemetic therapy.

Main Methods:

  • Review of interventions used for breakthrough emesis, including setrons, corticosteroids, and D2-receptor antagonists.

Related Experiment Videos

  • Analysis of modifications to antiemetic regimens for refractory emesis.
  • Assessment of the existing evidence base for antiemetic treatment strategies.

    • Main Results:

    • Suboptimal treatment of acute and delayed emesis is evident.
    • Various interventions are employed for breakthrough emesis, but their efficacy is not consistently documented.
    • Modifications to antiemetic regimens, such as adding D2-receptor antagonists or switching setrons, can help manage refractory emesis.

    Conclusions:

    • There is a lack of high-level (Level I or II) evidence-based guidelines for managing breakthrough and refractory emesis.
    • The area of managing difficult emesis remains poorly documented due to insufficient rigorous studies.
    • Further research is crucial to establish effective and evidence-based antiemetic treatment protocols.